Syngene International signs a 10-year deal with Zoetis in the US


Share post:

Biocon arm The 10-year-old agreement has been signed to produce the drug substance for Librela (a monoclonal antibody that treats osteoarthritis in dogs) with Zoetis, a US-based animal welfare company.

In 2011, Zoetis began a collaboration. Over the last 11 years, Syngene developed monoclonal antibody treatments for animal health. This includes developing and manufacturing clinical supplies for a treatment for allergic dermatitis or atopic dermatitis.

“This agreement, initially centred on Librela, paves the way for development and manufacturing of other molecules in the coming years and is expected to be worth up to $ 500 million to Syngene over 10 years, subject to regulatory approvals and market demand,” the company said on Thursday.

Librela or bedinvetmab, has already been launched in Europe and the UK, and won ‘Best new companion animal product’ by IHS Markit Connect in 2021 for its transformational impact on pain relief for canines.

Managing director and chief executive officer, Syngene International, Jonathan Hunt said: “We are delighted to be expanding our partnership with Zoetis. This multi-year deal marks a turning point for our Development and Manufacturing Services Division and I look forward to completing all the regulatory inspections. This 10-year agreement will position Syngene as a leading Contract Development and Manufacturing Organisation (CDMO) in animal health globally.”

“By advancing the next stage of Librela with Syngene, we continue to build a strong global supply network for Zoetis products and fulfill our purpose to nurture the world and humankind by advancing care for animal,” said Nick Ashton, executive vice president and president, global manufacturing and supply, Zoetis Inc.

Zoetis, a $7.8 billion animal health company has a large pipeline of medicines, diagnostics and vaccines.

Syngene on the other side does drug discovery work at all stages, including pre-clinical and clinical development. They also offer manufacturing services to their clients. This includes industries like pharmaceutical, biotech and nutrition as well as speciality chemicals.

Syngene clients make up around 74%.

“The global market for contract research was valued at $48.55 billion in 2020 and is expected to reach $83.34 billion growing at a CAGR of 9.4 per cent. Within this, the outsourcing market for drug discovery and early development services is expected to grow at a CAGR of 6.4 per cent over 2020-2026 to reach a value of $44 billion by the end of this period,” the company noted in its FY22 annual report.

Hunt, in the company’s annual report, stated that Syngene expecting strong demand for both biologics development and biologics manufacturing capacity.

“Recent investments in expanding both our mammalian and microbial facilities will put us into a strong position to capture some of that demand,” he added.

Dear Reader,

Business Standard has been committed to providing you with the most current information and commentary on the latest developments in the country and around the globe. We have been encouraged by you and received your constant feedback regarding how we can improve the quality of our service. We will continue to keep you updated, informed, and authoritative in our reporting on relevant topics, even during the difficult times that Covid-19 has brought.

However, we have a request.

Your support is essential as we fight the economic impact of this pandemic. We also need your continued support to continue offering you quality content. Many people have subscribed to our online content, which has received a positive response. Our goal is to offer you better and more relevant content by allowing you to subscribe more often. We believe in honest, fair, and credible journalism. We can use your support by obtaining more subscriptions to help us practice the journalism we believe in.

Support journalism of high quality Subscribe to Business Standard.

Digital Editor


Please enter your comment!
Please enter your name here


Related articles

The Benefits of a Creative Subscription with Envato Elements

If you’re looking to find and use royalty-free images and other creative resources, it can be tough to...

Get an Additional ₹100 Cashback When You Pay with Domino’s Digital Wallet Partners

How does ₹100 cashback sound? Find out more about the additional cashback you can get when you pay...

Get Unlimited Access to DataCamp’s Library of Online Courses

DataCamp subscriptions enable access to over 300 courses, as well as projects, assessments, and additional content. Whether you're...

Why You Should Buy from DaMENSCH: The Best in Quality, Service, and Value

Buying products online can be dangerous; you never know if you’re getting an authentic product, or one that’s...